Landos Biopharma Inc. (NASDAQ:LABP) went down by -25.35% from its latest closing price compared to the recent 1-year high of $4.48. The company’s stock price has collected -20.59% of loss in the last five trading sessions.
Is It Worth Investing in Landos Biopharma Inc. (NASDAQ :LABP) Right Now?
LABP currently public float of 30.40M and currently shorts hold a 1.19% ratio of that float. Today, the average trading volume of LABP was 591.12K shares.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could “deliver huge returns.” Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
LABP’s Market Performance
LABP stocks went down by -20.59% for the week, with a monthly jump of 76.32% and a quarterly performance of -41.73%, while its annual performance rate touched -91.00%. The volatility ratio for the week stands at 25.46% while the volatility levels for the past 30 days are set at 27.51% for Landos Biopharma Inc. The simple moving average for the period of the last 20 days is 2.78% for LABP stocks with a simple moving average of -46.50% for the last 200 days.
Analysts’ Opinion of LABP
Many brokerage firms have already submitted their reports for LABP stocks, with Jefferies repeating the rating for LABP by listing it as a “Hold.” The predicted price for LABP in the upcoming period, according to Jefferies is $1.40 based on the research report published on April 12th of the previous year 2022.
SVB Leerink, on the other hand, stated in their research note that they expect to see LABP reach a price target of $16, previously predicting the price at $20. The rating they have provided for LABP stocks is “Mkt Perform” according to the report published on November 16th, 2021.
Craig Hallum gave a rating of “Buy” to LABP, setting the target price at $45 in the report published on October 20th of the previous year.
LABP Trading at 25.19% from the 50-Day Moving Average
After a stumble in the market that brought LABP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.96% of loss for the given period.
Volatility was left at 27.51%, however, over the last 30 days, the volatility rate increased by 25.46%, as shares surge +79.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.58% upper at present.
During the last 5 trading sessions, LABP fell by -20.59%, which changed the moving average for the period of 200-days by -76.59% in comparison to the 20-day moving average, which settled at $0.4030. In addition, Landos Biopharma Inc. saw -19.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LABP starting from RTW INVESTMENTS, LP, who sale 300,000 shares at the price of $0.69 back on Sep 23. After this action, RTW INVESTMENTS, LP now owns 3,975,722 shares of Landos Biopharma Inc., valued at $207,000 using the latest closing price.
Stock Fundamentals for LABP
Current profitability levels for the company are sitting at:
- -215.64 for the present operating margin
- +98.91 for the gross margin
The net margin for Landos Biopharma Inc. stands at -213.46. Equity return is now at value -92.60, with -77.90 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.55.